Search
3 days ago
IntraBio, which moved from Oxford, UK to Austin, Texas last year, received FDA approval in September for its modified amino acid, AQNEURSA, to treat neurological manifestations of Niemann-Pick type C
President and CEO Professor Mallory Factor KCNG describes the mechanism of the therapy and the company's commercial launch and hiring....